Trials / Terminated
TerminatedNCT00042302
A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Paclitaxel/Carboplatin as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC)
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 540 (planned)
- Sponsor
- QLT Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine whether tariquidar + combined first-line chemotherapy of paclitaxel/carboplatin in patients with Stage IIIb/IV NSCLC will, with an acceptable safety profile, significantly improve overall survival compared with placebo + paclitaxel/carboplatin. To compare the effects of tariquidar/paclitaxel/carboplatin with placebo/paclitaxel/carboplatin on tumor response, time to disease progression, performance status, symptom progression, and quality of life in patients with Stage IIIb/IV NSCLC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Chemotherapy | |
| DRUG | tariquidar + paclitaxel/carboplatin | |
| DRUG | placebo + paclitaxel/carboplatin |
Timeline
- Start date
- 2002-06-01
- Primary completion
- 2003-07-01
- Completion
- 2003-07-01
- First posted
- 2002-08-01
- Last updated
- 2012-05-23
Source: ClinicalTrials.gov record NCT00042302. Inclusion in this directory is not an endorsement.